The bureaucracy blocking the chance at a cure
a day ago
- #medical-bureaucracy
- #clinical-trials
- #biotech-reform
- Bureaucratic red tape significantly delays and increases the cost of early-stage clinical trials, even for urgent and self-funded treatments.
- Examples include Paul Conyngham's struggle to get approval for his dog's mRNA vaccine and Sid Sijbrandij's battle with regulatory barriers for his cancer treatment.
- Early-stage trials are crucial for personalized medicine and rare diseases but are hindered by excessive regulatory requirements like IRB approvals and GMP standards.
- Australia's more efficient clinical trial framework shows that reforms can reduce costs and timelines without compromising safety.
- Proposed solutions include allowing investigator choice of IRBs, implementing a notification pathway for early-stage trials, and modifying GMP requirements to be more flexible.
- Regulatory opacity and high manufacturing costs force many biotech firms to move trials abroad, threatening U.S. leadership in biotechnology and biosecurity.
- Lowering barriers to early-stage trials could accelerate medical innovation, expand patient access to experimental treatments, and maintain U.S. competitiveness in biotech.